SCHEMBL10054833

SCHEMBL10054833

Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1NC(=O)/C=C/c1cncnc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.55
BRAF P15056 3/20 0.55
KIT P10721 15/20 0.55
ABL1 P00519 13/20 0.55
ABL2 P42684 9/20 0.55
BCR P11274 5/20 0.55
CSF1R P07333 5/20 0.55
LCK P06239 3/20 0.55
PDGFRA P16234 3/20 0.55
ERBB2 P04626 2/20 0.55
FYN P06241 2/20 0.55
LYN P07948 2/20 0.55
PDGFRB P09619 2/20 0.55
FGR P09769 2/20 0.55
SRC P12931 2/20 0.55
NQO2 P16083 2/20 0.55
EPHA8 P29322 2/20 0.55
FRK P42685 2/20 0.55
BLK P51451 2/20 0.55
DDR1 Q08345 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2679173 1.00 EGFR (0.55) EGFRBRAFKITABL1ABL2
SCHEMBL10054795 0.91 ABL1 (0.63) EGFRBRAFKITABL1ABL2
SCHEMBL2679249 0.91 ABL1 (0.63) EGFRBRAFKITABL1ABL2
SCHEMBL2678927 0.90 BRAF (0.60) EGFRBRAFKITABL1BCR
SCHEMBL10054847 0.90 BRAF (0.60) EGFRBRAFKITABL1BCR
SCHEMBL10054809 0.88 ABL1 (0.61) EGFRBRAFKITABL1ABL2
SCHEMBL2680093 0.88 BRAF (0.60) EGFRBRAFKITABL1BCR
SCHEMBL10054840 0.88 BRAF (0.60) EGFRBRAFKITABL1BCR
SCHEMBL2679074 0.86 BRAF (0.75) EGFRBRAFKITABL1BCR
SCHEMBL10054834 0.86 BRAF (0.75) EGFRBRAFKITABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 US disclosed
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 US disclosed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 US disclosed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament ABL1, ABL2, BCR EGFR 40/4885BRAF 21/4885KIT 399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.